Keon Uk Park (Keon-Uk Park)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Clinical Practice

Positron Emission Tomography

Small Cell Lung Cancer

Top Venues

Expert opinion on biological therapy

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Min-Ho Park, Jae Hong Seo, Jung Ho Park, Min-Ki Seong, Keon Uk Park, Min Kyoon Kim, Myung Chul Chang, Su Jin Koh, Moon Hee Lee, Seung Taek Lim, Young-Bum Yoo, So Yeon Oh, Sung Hyun Kim, Keum Young Ahn, Tae Hong Park, Hana Ju, Eric Hyungseok Baek, Sinhye Kim, Nahyun Kim, Eunkyung Lee, Tae Hyun Kim
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study. Expert opinion on biological therapy 24 (4) (2024)
Min-Ho Park, Jae Hong Seo, Jung Ho Park, Min-Ki Seong, Keon Uk Park, Min Kyoon Kim, Myung Chul Chang, Su Jin Koh, Moon Hee Lee, Seung Taek Lim, Young-Bum Yoo, So Yeon Oh, Sung Hyun Kim, Keum Young Ahn, Tae Hong Park, Hana Ju, Eric Hyungseok Baek, Sinhye Kim, Nahyun Kim, Eunkyung Lee, Tae Hyun Kim
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study. Expert opinion on biological therapy 24 (4) (2024)
Min-Ho Park, Jae Hong Seo, Jung Ho Park, Min-Ki Seong, Keon Uk Park, Min Kyoon Kim, Myung Chul Chang, Su Jin Koh, Moon Hee Lee, Seung Taek Lim, Young-Bum Yoo, So Yeon Oh, Sung Hyun Kim, Keum Young Ahn, Tae Hong Park, Hana Ju, Eric Hyungseok Baek, Sinhye Kim, Nahyun Kim, Eunkyung Lee, Tae Hyun Kim
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study. Expert opinion on biological therapy 24 (4) (2024)
Min-Ho Park, Jae Hong Seo, Jung Ho Park, Min-Ki Seong, Keon Uk Park, Min Kyoon Kim, Myung Chul Chang, Su Jin Koh, Moon Hee Lee, Seung Taek Lim, Young-Bum Yoo, So Yeon Oh, Sung Hyun Kim, Keum Young Ahn, Tae Hong Park, Hana Ju, Eric Hyungseok Baek, Sinhye Kim, Nahyun Kim, Eunkyung Lee, Tae Hyun Kim
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study. Expert opinion on biological therapy (2024)
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, Sangwoo Kim, Hye Ryun Kim, Hwan Jung Yun, null null
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hyun Ae Jung, Keon Uk Park, Sang Hee Cho, Jinyeong Lim, Keun-Wook Lee, Min Hee Hong, Tak Yun, Ho Jung An, Woong-Yang Park, Sergio Pereira, Chan-Young Ock, Bhumsuk Keam
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Young Joo Lee, Hye Ryun Kim, Min Hee Hong, Ki Hyeong Lee, Keon Uk Park, Geon Kook Lee, Hyae Young Kim, Soo-Hyun Lee, Kun Young Lim, Sung Jin Yoon, Byoung Chul Cho, Ji-Youn Han
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. Cancer (2022)
Min Hee Hong, Seong Gu Heo, Yun-Gyoo Lee, Hyo Song Kim, Keon Uk Park, Hoon-Gu Kim, Yoon Ho Ko, Ik-Joo Chung, Young Joo Min, Min Kyoung Kim, Kyu Ryung Kim, Jinseon Yoo, Tae-Min Kim, Hye Ryun Kim, Byoung Chul Cho
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. Cancer 126 (20) (2020)